-

Shareholder Alert: Robbins LLP Announces That it is Investigating XL Fleet Corp. (XL) on Behalf of Shareholders

SAN DIEGO & BOSTON--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating XL Fleet Corp. (NYSE: XL) to determine whether certain XL Fleet Corp. officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. XL Fleet provides vehicle electrification solutions for commercial and municipal fleets in North America. It offers hybrid and plug-in hybrid electric drive systems.

If you suffered a loss due to XL Fleet Corp.'s misconduct, click here.

XL Fleet Corp. (XL) Misled Shareholders About its Business Prospects

XL Fleet formed via merger of XL Hybrids, Inc. and Pivotal Investment Corporation II, a special purpose acquisition company, on December 22, 2020. In its Registration Statement seeking shareholder approval of the merger, Pivotal stated that XL Hybrids relies on a limited number of customers for a large portion of its revenue and that the loss of one or more customers could materially and adversely impact its business operations. The Registration Statement also indicated that delays in design, production, and launch of its products could also harm its business, financial condition, and operating results. After the merger, XL Fleet touted its financial results, stating, "the third quarter of 2020 was the highest for a single quarter in the Company's history," as well as its contracts and product offerings.

On March 3, 2021, Muddy Waters Research published a report alleging that salespeople at XL Fleet Corp. "were pressured to inflate their sales pipelines materially in order to mislead XL's board and investors" and that "customer reorder rates are in reality quite low" due to "poor performance and regulatory issues." Citing interviews with former employees, the report alleges, "at least 18 of 33 customers XL featured were inactive." Muddy Waters also claims that XL Fleet did not generate claimed ROIs for customers and that its technology is "weak." On this news, the Company's share price fell $2.09, or 13%, to close at $13.86 per share on March 3, 2021. The price share continued to decline over two trading sessions to close at $11.17 per share on March 5, 2021.

XL Fleet Corp. (XL) Shareholders Have Legal Options. If you would like more information regarding your rights, please contact Lauren Levi at (800) 350-6003 or llevi@robbinsllp.com, or via our Shareholder Information Form.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against XL Fleet Corp. settles or to receive free alerts about company executives engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom